Targeted Therapy for BRAFV600E Malignant Astrocytoma
暂无分享,去创建一个
Barbara S. Paugh | J. Hodgson | C. James | S. Hariono | D. Rowitch | T. Forshew | Chris Jones | S. Baker | T. Waldman | W. Weiss | D. Solomon | Jung‐Sik Kim | R. Hashizume | T. Nicolaides | G. Hindley | Huifang Li | Krister J. Barkovich
[1] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[2] T. Zhou,et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. , 2011, Neuro-oncology.
[3] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[4] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[5] A. Ashworth,et al. A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas , 2010, Clinical Cancer Research.
[6] Richard G Grundy,et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Prados,et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.
[8] M. Berger,et al. Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. , 2010, Neuro-oncology.
[9] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[10] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[11] C. Hawkins,et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[13] Hanlee P. Ji,et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.
[14] R. Beroukhim,et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. , 2009, Cancer cell.
[15] Susan M. Chang,et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Caterina Giannini,et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Sastre,et al. The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFRamplification , 2008, Neuropathology : official journal of the Japanese Society of Neuropathology.
[18] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[19] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[20] F. Lovat,et al. p27Kip1 expression inhibits glioblastoma growth, invasion, and tumor-induced neoangiogenesis , 2008, Molecular Cancer Therapeutics.
[21] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[22] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[23] Chunxu Qu,et al. EWS/FLI-1 Induces Rapid Onset of Myeloid/Erythroid Leukemia in Mice , 2007, Molecular and Cellular Biology.
[24] P. Wesseling,et al. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations , 2007, Acta Neuropathologica.
[25] D. Morrison,et al. Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.
[26] I. Pollack,et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. , 2007, Neuro-oncology.
[27] C. James,et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel , 2007, Molecular Cancer Therapeutics.
[28] A. Aplin,et al. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells , 2007, Oncogene.
[29] C. James,et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. , 2006, Journal of neurosurgery.
[30] H. Ressom,et al. Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA , 2006, Molecular and Cellular Biology.
[31] S. Shete,et al. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. , 2006, Journal of neurosurgery.
[32] B. Anandh,et al. Expression of p53, EGFR, pRb and bcl-2 Proteins in Pediatric Glioblastoma Multiforme: A Study of 54 Patients , 2005, Pediatric Neurosurgery.
[33] M. McMahon,et al. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. , 2005, Cancer research.
[34] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[35] J. Sebolt-Leopold,et al. Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.
[36] Richard Marais,et al. The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.
[37] G. Reifenberger,et al. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas , 2004, Acta Neuropathologica.
[38] B. Weber,et al. SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant , 2004, Cancer Research.
[39] Siegfried Kropf,et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. , 2003, International journal of oncology.
[40] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[41] I. Pollack,et al. Expression of p53 and prognosis in children with malignant gliomas. , 2002, The New England journal of medicine.
[42] I. Pollack,et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. , 2001, Cancer research.
[43] J. Vincent,et al. Raf‐1 and B‐Raf proteins have similar regional distributions but differential subcellular localization in adult rat brain , 1999, The European journal of neuroscience.
[44] Y. Yonekawa,et al. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. , 1997, Journal of neuropathology and experimental neurology.
[45] C. Marshall,et al. Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases* , 1997, The Journal of Biological Chemistry.
[46] J. Pouysségur,et al. Cyclin D1 Expression Is Regulated Positively by the p42/p44MAPK and Negatively by the p38/HOGMAPK Pathway* , 1996, The Journal of Biological Chemistry.
[47] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .